Previous Article | Next Article ![]()
Journal of Virology, August 2009, p. 7739-7748, Vol. 83, No. 15
0022-538X/09/$08.00+0 doi:10.1128/JVI.00614-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands,1 Laboratory of Clinical Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands,2 Institute for Virology, University of Bonn Medical Centre, Bonn, Germany3
Received 25 March 2009/ Accepted 18 May 2009
|
|
|---|
|
|
|---|
Presently, the Bocavirus genus includes bovine parvovirus (BPV), minute virus of canines (MVC), and the recently identified human bocavirus (HBoV) and HBoV type 2 (2, 9, 15). HBoV was identified in 2005 within pools of human nasopharyngeal aspirates obtained from individuals with respiratory tract illnesses. The current genomic DNA reference sequence of HBoV is 5,299 nt in length, but sequence information regarding the flanking terminal hairpin structures remains to be determined (2). HBoV has been found worldwide, mainly in respiratory samples, but in some cases, HBoV has also been detected in serum, fecal samples, and urine samples (1, 16, 20, 31). HBoV infections are frequently diagnosed in <2-year-old children with upper or lower respiratory tract illness, often in combination with another respiratory virus (2, 16, 20). One of the most frequently observed clinical symptoms in HBoV-infected patients is acute wheezing (1). Despite the current knowledge regarding HBoV, no in vitro or in vivo model that supports replication of HBoV has been established.
In this study, we investigated whether pseudostratified human airway epithelium cell culture could be utilized as a model for HBoV replication. Pseudostratified epithelium is formed by culturing primary human airway epithelial cells in an air-liquid interface. The morphology and functionality of the cells resemble those of the human airways, and this system has been used previously to culture a wide range of respiratory viruses, e.g., influenza virus (28), parainfluenza virus (33), respiratory syncytial virus (34), adenovirus (21), and severe acute respiratory syndrome coronavirus (26). In this study, we documented HBoV replication upon inoculation with respiratory material from HBoV-infected patients. We observed apical release of virus and analyzed the viral mRNA transcripts in the infected cells.
|
|
|---|
Human airway epithelial cell culture. Cryopreserved human trachea epithelial primary cells (HTEpC) were obtained from the European Collection of Cell Cultures. HTEpC were maintained for one serial passage as a monolayer in bronchial/tracheal epithelial cell serum-free growth medium (European Collection of Cell Cultures) supplemented with penicillin-streptomycin. Bronchial/tracheal epithelial cell serum-free growth medium was refreshed every 2 or 3 days. HTEpC cultures were maintained at 37°C in a 5% CO2 incubator. When reaching 75% confluence, cells were dissociated with 2 ml of TrypLE Express enzyme (Invitrogen). HTEpC were diluted in air-liquid interface medium (11), which is a mixture of LHC basal medium (Invitrogen) and Dulbecco's modified Eagle's medium (Invitrogen) supplemented with the required additives (Sigma). A total of 8 x 104 HTEpC were seeded on type IV collagen (Sigma)-coated 12-well ThinCerts with a 0.4-µm pore size (Greiner Bio-One). Medium was renewed every 2 or 3 days. When cultures reached full confluence, the cells were exposed to air. HTEpC cultures on the air-liquid interface were maintained in 12-well deep-well plates (Greiner Bio-One) for 21 days to let the cells differentiate into pseudostratified human airway epithelial cell cultures. Medium from the basolateral compartment was renewed every 6 days, and the apical surface was washed every 2 days with Hanks balanced salt solution (HBSS) (Invitrogen).
HBoV infection. An aliquot of 50 µl clinical patient material was diluted in 200 µl HBSS and centrifuged for 30 min at 4°C with 10,000x relative centrifugal force. Two hundred microliters of diluted clinical sample was directly inoculated upon the apical surface of pseudostratified human airway epithelium and incubated for 2 h at 34°C in a 5% CO2 incubator. After 2 h, 200-µl samples were collected from both the apical and basolateral sides. Inoculated cultures were maintained at 34°C in a 5% CO2 incubator. Samples were collected after 24, 48, 72, and 95 h postinoculation (hpi) from both the apical and basolateral sides. Apical washing and harvesting was performed by adding 200 µl of HBSS to the apical surface and incubation for 10 min at 34°C in a 5% CO2 incubator, followed by the removal and storage of the 200 µl HBSS from the apical surface. Washing is needed to remove the mucus, which will otherwise suffocate the cells. An aliquot of 50 µl apical wash was transferred into 900 µl L6 lysis buffer (6) for HBoV DNA quantification. At the last day of culture, the cells were collected in TRIzol reagent (Invitrogen) for HBoV mRNA analysis. Cultures were transferred to a conventional 12-well plate (Greiner Bio-One) and analyzed by eye with a phase-contrast microscope, prior to cell collection in TRIzol reagent.
HBoV yield. Viral DNA was isolated from the collected samples of the apical and basolateral harvests by the Boom method for total nucleic acid isolation (6), and elution was performed in 100 µl H2O. Real-time PCRs were performed on the HBoV NS1 gene region. Primer and probe details are available upon request (unpublished data).
DNase protection assay of HBoV DNA from the Bonn-1 culture. An aliquot of 50 µl apical and basolateral harvest of the Bonn-1 isolate was spiked with 25 µl naked plasmid DNA containing a part of phocid herpesvirus-1 DNA (250 DNA copies/µl) and 5 µl cell culture supernatant of human adenovirus type 5 (1E8 50% tissue culture infective doses/ml). Eighty microliters of the spiked sample was incubated with 18 units of DNase I (Ambion) in a total volume of 100 µl for 45 min at 37°C, followed by total nucleic acid isolation (Boom) as described above. Real-time PCRs for HBoV were performed as described above. The design and characteristics of the phocid herpesvirus-1 and adenovirus real-time PCR are available upon request. In all samples, naked plasmid DNA was degraded (>2-log decrease), whereas adenoviral DNA inside a virus particle was protected from DNase treatment (<1-log decrease) (data not shown).
Full-genome sequencing. The complete genome sequence of the HBoV Stockholm 2 isolate (NC_007455) was used as the template for designing bidirectional primer combinations encompassing 5,299 nt. Primer combinations had an average theoretical fragment length of 600 bp with a minimum overlap of 70 bp with adjacent primer combinations. All primers match identical regions of the most recent available full-genome sequences of different HBoV isolates with the BLAST sequence alignment tool (24). Primer sequences are available upon request. Amplification of the fragment was performed with a thermal cycle profile as follows: 95°C for 5 min; 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, followed by a final elongation step at 72°C for 10 min. PCR fragments were visualized upon agarose gel electrophoreses by ethidium bromide staining. Positive PCR fragments were directly sequenced with their respective PCR primers. A sequence reaction was performed without purifying steps, according to the BigDye Terminator version 1.1 cycle sequencing manufacturer protocol (Applied Biosystems) on a GeneAmp PCR system 9700 thermal cycler (Perkin Elmer). Electrophoresis and data collection was performed on a 3100 genetic analyzer (Applied Biosystems). Raw collection data was processed and analyzed with Codoncode Aligner v2.06 software (CodonCode Corporation).
5' and 3' RACE of HBoV mRNA. Cellular mRNA was isolated from whole-cell lysate of the pseudostratified human airway epithelium cell culture in TRIzol reagent, according to the manufacturer's protocol (Invitrogen). Elution was performed in 200 µl of diethyl pyrocarbonate-treated water. Eighty microliters of a whole cellular mRNA fraction was incubated with 18 units of DNase I (Ambion) in a total volume of 100 µl for 45 min at 37°C. The DNase-treated fraction was subsequently phenol-chloroform (Invitrogen) extracted, and this was followed by an overnight ethanol precipitation. The 5' sequences of the mRNA transcripts were determined with a 5' system for rapid amplification of cDNA ends (RACE system, version 2.0; Invitrogen), according to the manufacturer's protocol. Gene-specific RT and PCR primers were designed based on the predicted NS1, NP1, VP1, and VP2 and the putative ORFx gene (Table 1). Gene-specific primers for 5' RACE PCR amplification were designed to flank approximately 100 nt of the 5' region of the predicted start codon positions of the open reading frames (ORFs). The 3' ends of HBoV mRNA transcripts were determined with a 3' RACE system (Invitrogen) according to the manufacturer's protocol with minor modifications. RT was performed with the JZH-OligodT primer (5'-GCTATCATCACAATGGACTTTTTTTTTTTTTTTTTTV-3'), and PCR amplification was performed with the JZH-Nested adaptor primer (5'-GCTATCATCACAATGGAC-3') and a gene-specific primer (Table 1). The PCR products were excised after agarose electrophoresis and purified with the NucleoSpin Extract II kit (Machery-Nagel) according to the manufacturer's protocol. Purified PCR products were cloned into the pCR2.1-TOPO TA vector (Invitrogen) and transformed in chemically competent TOP10 Escherichia coli (Invitrogen), according to manufacturer protocol. Transformants were directly analyzed via colony PCR with T7 and M13RP primers. PCR products were sequenced as described above.
|
View this table: [in a new window] |
TABLE 1. Primers for HBoV mRNA analysis
|
Nucleotide sequence accession number. The genome sequence of the Bonn-1 isolate has been submitted to GenBank under accession number FJ858259.
|
|
|---|
![]() View larger version (16K): [in a new window] |
FIG. 1. HBoV propagation on human airway epithelium cell culture. HBoV DNA concentration (copies of DNA/ml; y axis) in the apical washings at different hours postinoculation (x axis) for the Bonn-1 (A), Bonn-2 (B), and Bonn-3 (C) HBoV-inoculated human airway epithelium cell cultures. HBoV DNA quantification at the basolateral side is shown in panels D (Bonn-1), E (Bonn-2), and F (Bonn-3). The horizontal dashed line represents the detection threshold of the HBoV DNA real-time PCR assay.
|
![]() View larger version (17K): [in a new window] |
FIG. 2. DNase protection assay of HBoV DNA from the Bonn-1 culture. HBoV DNA concentration (copies of DNA/ml; y axis) in DNase-treated (continuous line) and non-DNase-treated (dashed line) apical harvests (A) and basolateral harvests (B). The horizontal dashed line in panel A represents the detection threshold of the assay.
|
HBoV transcription. The apical release of Bonn-1 virus particles demonstrates viral replication, yet further evidence of productive infection can be obtained by measuring intracellular viral mRNA transcripts. This can be done by Northern blotting; however, this was not possible, due to the low number of cells in this culture system. Alternatively, the mRNAs can be investigated by 5' RACE and 3' RACE. For primer design, we first established the viral genome sequence; more specifically, we obtained this information for the ORFs in the Bonn-1 isolate. As a template for sequencing, we used the apical washing of Bonn-1 at 95 hpi. The acquired genomic sequence encompasses 5,299 nt with an overall similarity of 99.8% with the HBoV ST2 reference sequence (NC_007455) and 97.9% with the HBoV ST1 reference sequence (DQ000495). In silico analysis of the putative ORFs within the Bonn-1 genomic sequence resulted in four hits: the NS1, NP1, and VP1/VP2 genes and one additional putative gene (ORFx) encoding a 120 amino acid protein that has not been described previously. The deduced amino acid sequence of the ORFx protein has no viral or cellular homologue. The deduced amino acid sequences of the putative NS1 and NP1 proteins of Bonn-1 shared 100% homology with those of the HBoV ST2, and for the VP1/VP2 protein, the shared homology is 99%.
The 5' terminal sequence of the various mRNAs was determined by 5' RACE with primers annealing in NS1, NP1, VP1, VP2, and ORFx (Table 1). Only with NS1, NP1, and VP1 primers was the 5' RACE positive (Fig. 3A). The NP1 and VP1 5' RACE products display two fragments, and the NS1 product displays only one. Sequencing of the fragments revealed that all three transcripts start at position 186 (Fig. 3B). Prediction of promoter regions with the neural network promoter prediction software (version 2.2) indeed shows that at positions 146 to 196, a promoter region (5'-TATTAAACCTATATAAGCTGCTGCACTTCCTGATTCAATCAGACTGCATC-3' [the putative TATA box is underlined and the starting nucleotide is in boldface) is present, and our 5' RACE experiments suggest that it is the only promoter used (23). The 5' RACE experiment further revealed that the transcript containing the NS1 gene was not spliced at the 5' terminus (mRNA 1; Fig. 3B and 4). This was not the case for the mRNAs that contained the NP1 gene and the VP1 gene, which are the products of alternative splicing. There are two transcripts that contain the NP1 gene (mRNA 2 and mRNA 3; Fig. 3B and 4). In mRNA 2, only one splicing event occurred (donor 241 and acceptor 2236), whereas in the other mRNA (mRNA 3), splicing occurred twice (donor 241 and acceptor 2044 and donor 2164 and acceptor 2236) (Fig. 3B and 4). In mRNA 3, the sequence between positions 2044 and 2164 is retained in the mRNA.
![]() ![]() View larger version (55K): [in a new window] |
FIG. 3. Identification of mRNA transcripts from Bonn-1. (A) Agarose gel with ethidium bromide-stained 5' RACE PCR products of NS1, NP1, and VP1 mRNAs of the Bonn-1 isolate at 95 hpi. The arrows indicate 5' RACE-amplified PCR products. (B) The determined cDNA nucleotide sequences of the NS1, NP1, and VP1 5' RACE products. The start position of each transcript is indicated at the beginning of the nucleotide sequence. The spectrum of color highlights the nucleotide sequences corresponding with different regions along the genome. The genome positions at the splice donor and acceptor junction sites are shown in parentheses. The first start codon triplets along each fragment are indicated in underlined black letters. In mRNA 1, the start codon is for NS1; for mRNA 2, the start codon is for NP1; for mRNA 3, the start codon is for UP1; for mRNA 4, the start codon is for VP1; and for mRNA5, the start codon is for UP2. The binding region of the reverse 5' RACE primer is shown in italics. (C) Agarose gel with ethidium bromide-stained 3' RACE products of the NP1 and VP2 mRNAs of the Bonn-1 isolate at 95 hpi. The arrows indicate 3' RACE-amplified PCR products that were properly primed on the polyadenosine tails. The additional fragments were generated by nonspecific priming of the RT primer at polyadenosine stretches along the HBoV genome. (D) The determined cDNA nucleotide sequences of the VP2 and NP1 3' RACE products. The forward 3' RACE primer is shown in italics. The position of the stop codon of the NP1 and VP2 transcripts is indicated with underlined black letters, and the proximal polyadenylation [(pA)p] (NP1 3'RACE products) and distal pA [(pA)d] (VP2 3'RACE product) are underlined. The genome position of the stop codon and the pA sites are indicated above the sequence.
|
![]() View larger version (21K): [in a new window] |
FIG. 4. Schematic representation of the genomic and transcriptional map of HBoV Bonn-1 isolate. The transcriptional start (arrow), the splice donor (D numbers) and acceptor (A numbers) sites, the proximal and distal polyadenylation signals [pA(p) and pA(d), respectively], and the predicted ORFs are positioned along the HBoV genome of the Bonn-1 isolate. In the lower panel, a schematic overview of the identified mRNA transcripts of Bonn-1 HBoV and their suggested protein products is presented.
|
Subsequently, we determined the 3' terminal sequence of the viral mRNA transcripts to investigate whether splicing occurs downstream of the ORFs and to identify the polyadenylation signals of each mRNA. Unfortunately, the 3' RACE with NS1 gene-specific primers did not yield any PCR product, suggesting that the polyadenylation signal is located far from the 3' terminus of the ORF. We decided to further investigate the NS1 transcript by RT-PCR using a 5' primer specific to the NS1 gene and 3' primers in the NP1 gene or further downstream. This revealed that the complete NP1 gene is situated adjacent to the NS1 gene. Furthermore, RT-PCR with a 3' primer at position 3605 was negative (data not shown). This suggests that NS1 mRNA is polyadenylated downstream of the NP1 gene.
The 3' RACE results with NP1 and VP2 gene-containing transcripts were positive (Fig. 3C). The VP2 PCR fragment of approximately 100 bp and the NP1 PCR fragment of approximately 790 bp (Fig. 3C) were properly primed on a polyadenosine tail and revealed that the NP1 containing mRNAs are polyadenylated at two positions proximal to the 3' terminus of the NP1 gene (position 3219 and 3260; Fig. 3D). Upstream of position 3219, a polyadenylation signal is present (position 3199), there is also a polyadenylation signal situated upstream of position 3260 (position 3233; Fig. 3D), and we conclude that both polyadenylation signals proximal to the NP1 gene are in use. The VP2 gene-containing transcript is polyadenylated at position 5075, downstream of a polyadenylation signal at position 5057 (Fig. 3D).
With the identification of the spliced mRNAs, we provide further evidence that a productive HBoV infection was established. For a final control, we tested whether the spliced mRNA could have originated from the clinical samples themselves, instead of being produced in the infected cells. An RT-PCR on the 5' terminus of the NP1 gene-containing mRNAs was performed on the input materials (0 hpi; Fig. 5) and the cellular RNA at 95 hpi. All clinical samples, including Bonn-1, were negative for spliced mRNA, whereas at 95 hpi, the spliced NP1 mRNAs are present in the cellular mRNA pool of the Bonn-1 virus-inoculated culture (Fig. 5).
![]() View larger version (25K): [in a new window] |
FIG. 5. Spliced mRNAs are not present in the inoculum. Agarose gel with ethidium bromide-stained RT-PCR products. Primers spanning the splice junctions in the NP1 mRNA were used for amplification (primers BOCA_5UTR1 and BOCA_R12; Table 1). At 95 hpi, the spliced mRNA RT-PCR is positive (mRNA 2, 445 bp; mRNA 3, 565 bp) for the Bonn-1 HBoV, whereas the inoculum did not contain HBoV mRNA (0 hpi).
|
Also in mRNA 3, the genome segment from positions 2044 to 2164 is included. Inspection of mRNA 3 reveals that in the case that the position 2116 AUG is used, a protein (UP1) of 161 amino acids is generated. The first 17 amino acids of UP1 and UP2 are identical to amino acids 622 to 638 of the NS1 protein.
|
|
|---|
The difficulty of isolating respiratory viruses from clinical material on conventional cell lines has been described in the mid-1960s, leading to ex vivo culturing of human embryo respiratory tract explants (29, 30). Nowadays, the usage of human embryo respiratory tract explants raises ethical issues, but efforts to isolate HBoV from clinical respiratory material on conventional cell lines, like LLC-MK2, HEp-2, Vero, and MRC-5 cells were not successful (10, 19, 35). It is likely that these cell lines are not susceptible to certain respiratory viruses, e.g., because they are deficient in receptor expression or no longer exhibit their cell-specific phenotypes, such as basal, secretory, and ciliated cells. We show that pseudostratified human airway epithelium cell culture is a convenient tool for the isolation and characterization of newly identified respiratory viruses that cannot be cultured on cell lines. This culture system morphologically and functionally resembles the human airways in vivo, and the susceptibility toward viruses coincides with the degree of differentiation. The system also allows characterization of the mode of release and infection of a virus, a major advantage over the respiratory tract explants.
The transcription profile that we present for HBoV displays features that are similar to the transcription map of the closely related BPV and MVC, which belong to the same Bocavirus genus (22, 27). The NS1 mRNAs of BPV and MVC are not spliced, similar what we show for HBoV. Downstream of the NS1 gene, the complete NP1 gene is present on the NS1 mRNA of HBoV. The same has been found in MVC (mRNA R1 and mRNA R2) and in BPV (mRNA R1b), yet in BPV, one of the NS1 mRNAs (R1a) is polyadenylated upstream of the stop codon of NP1 (22, 27). It is, however, unlikely that the NP1 protein of the bocaviruses is expressed from the nonspliced NS1 gene-containing mRNA. In HBoV, the pre-mRNA is alternatively spliced, and the spliced mRNAs are probably used for translation of NP1, VP1, and VP2. In BPV and MVC, two NP1 mRNAs which differ in the site of polyadenylation are found (22, 27). We detected two HBoV NP1 mRNAs (mRNA 2 and mRNA 3) that differ due to alternative splicing. Alternative splicing is also operational for the HBoV transcripts containing the VP1/VP2 ORF. There are two forms, one which is double spliced (mRNA 4) and one which is triple spliced (mRNA 5). Also, in MVC- and BPV-infected cells, two mRNAs that encode VP1/VP2 are generated. One mRNA is spliced once, and the other is spliced three times. The implications of the two alternatively spliced VP1/VP2 mRNAs have not been reported for either BPV or MVC (22, 27). The most remarkable HBoV transcript feature we found was the creation of an ORF by splicing in mRNA 3 and mRNA 5. Due to the retaining of a small part of the NS1 gene, these mRNAs have the potential to encode two previously unknown viral proteins: UP1 and UP2 (18.1 and 8.6 kDa, encoded by mRNA 3 and mRNA 5, respectively). The proteins display no clear homology with other known viral or cellular proteins, and future research is needed to determine whether expression occurs during infection.
The transcript map that we propose was determined for an ST2 type HBoV. Inspection of the ST1 complete genome sequences in GenBank revealed that ST1 will probably generate the same five mRNAs, because the promoter and all splice donor and acceptor sites are conserved for ST1 and ST2 strains. In the case that splicing in ST1 occurs in an manner identical to that in ST2 also, the putative UP1 and UP2 proteins can be produced, as the start and stop codons of UP1 and UP2 are present in the ST1 genomes. Even the ORFx gene is present in ST1 and ST2 strains, although not in all isolates. The reference sequence of ST1 (DQ000495) contains a stop codon 175 nt downstream of the AUG codon, and the ST2 strains from Taiwan (EU984241, EU984240, EU984236, EU984239, EU984242, EU984231, and EU984245) contain an AUG which is located 24 nt upstream of the ST2 ORFx AUG codon. Whether the ORFx protein of ST1 and ST2 is produced during infection is a question that will be subject to future research. We analyzed whether ORFx could be alternatively expressed via an IRES and identified a putative IRES of 98 nt in length located directly upstream of the putative ORFx gene on mRNA transcripts 4 and 5 (data not shown). Translation of ORFs located within the coding region of the VP2 mRNA is not an unusual feature of the parvovirus family (32). Still, whether the IRES is functional remains to be determined.
The capacity to culture HBoV broadens the scope of research possibilities, among which are the identification of the cellular receptor and tropism. Furthermore, and perhaps most important, it provides the possibility to analyze antiviral compounds for their capacity to inhibit viral replication.
We thank Eric Claas for providing HBoV primer and probe sequences, Marta Canuti for useful discussions, and Ben Berkhout for critical reading of the manuscript.
Published ahead of print on 27 May 2009. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2010 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»